U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C27H26N4O5S
Molecular Weight 518.584
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GSK-256066

SMILES

COC1=CC(NC2=C(C=NC3=C(C)C=C(C=C23)S(=O)(=O)C4=CC=CC(=C4)C(=O)N(C)C)C(N)=O)=CC=C1

InChI

InChIKey=JFHROPTYMMSOLG-UHFFFAOYSA-N
InChI=1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)

HIDE SMILES / InChI

Molecular Formula C27H26N4O5S
Molecular Weight 518.584
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

GSK-256066 is a PDE4B inhibitor which was developed by GlaxoSmithKline and tested in phase II of clinical trials for the treatment of COPD, Asthma and Seasonal allergic rhinitis. According to the GSK pipeline, development of GSK-256066 was terminated. There are studies that describes the possibility of repurposing of the drug as antitrypanosomal agents, because it inhibits PDEB1 of Trypanosoma brucei.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.2 pM [IC50]
10.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Curative
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.3 pg/mL
87.5 μg single, respiratory
dose: 87.5 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
GSK-256066 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17.3 pg/mL
8.75 μg 1 times / day multiple, respiratory
dose: 8.75 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
GSK-256066 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
36.8 pg × h/mL
87.5 μg single, respiratory
dose: 87.5 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
GSK-256066 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
64.8 pg × h/mL
8.75 μg 1 times / day multiple, respiratory
dose: 8.75 μg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
GSK-256066 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.
2010 Mar 1
Patents

Sample Use Guides

COPD: 25 or 87.5 mcg should be inhaled once daily. Asthma: patients receive inhaled drug at a dose of 87.5 mcg once per day.
Route of Administration: Other
LPS-stimulated TNFalpha expression was inhibited in PBMCs and whole blood using 10(-4)-10 nM of GSK-256066.
Substance Class Chemical
Created
by admin
on Sat Dec 16 07:27:54 UTC 2023
Edited
by admin
on Sat Dec 16 07:27:54 UTC 2023
Record UNII
2D6GK059SR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GSK-256066
Common Name English
3-QUINOLINECARBOXAMIDE, 6-((3-((DIMETHYLAMINO)CARBONYL)PHENYL)SULFONYL)-4-((3-METHOXYPHENYL)AMINO)-8-METHYL-
Systematic Name English
GSK256066
Code English
Code System Code Type Description
PUBCHEM
9827968
Created by admin on Sat Dec 16 07:27:54 UTC 2023 , Edited by admin on Sat Dec 16 07:27:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID30230090
Created by admin on Sat Dec 16 07:27:54 UTC 2023 , Edited by admin on Sat Dec 16 07:27:54 UTC 2023
PRIMARY
FDA UNII
2D6GK059SR
Created by admin on Sat Dec 16 07:27:54 UTC 2023 , Edited by admin on Sat Dec 16 07:27:54 UTC 2023
PRIMARY
DRUG BANK
DB12137
Created by admin on Sat Dec 16 07:27:54 UTC 2023 , Edited by admin on Sat Dec 16 07:27:54 UTC 2023
PRIMARY
SMS_ID
300000042397
Created by admin on Sat Dec 16 07:27:54 UTC 2023 , Edited by admin on Sat Dec 16 07:27:54 UTC 2023
PRIMARY
CAS
801312-28-7
Created by admin on Sat Dec 16 07:27:54 UTC 2023 , Edited by admin on Sat Dec 16 07:27:54 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY